HENDERSON MICHAEL THOMAS 4

What Happened Michael T. Henderson, CEO of Apogee Therapeutics (APGE), sold 80,000 shares in an open-market transaction on June 22, 2026. The weighted-average sale price was $132.54 per share, producing gross proceeds of approximately $10,603,200. The sale was executed in multiple trades (prices ranged $132.50–$132.68) and is reported as a disposition (S).

Key Details

• Transaction date: June 22, 2026; Form filed June 24, 2026 (timely filing).
• Shares sold: 80,000; weighted-average price: $132.54; price range: $132.50–$132.68.
• Gross proceeds: ~$10,603,200.
• Post-transaction holdings: Not provided in the excerpt supplied — see the full Form 4 for shares owned after the sale.
• Footnotes: (1) Sale executed pursuant to a Rule 10b5-1 trading plan adopted August 13, 2025. (2) Reported price is a weighted average; the filer can provide a per-trade breakdown on request.
• Transaction type: Open-market sale (Form 4 code S).

Context Sales executed under an established 10b5-1 plan are pre-arranged and often reflect scheduled, routine disposition rather than a real-time judgment about the company's prospects. This report is factual — it confirms the CEO reduced holdings and the proceeds involved; it does not indicate motivation. For exact per-trade details or the insider's remaining holdings, consult the full SEC Form 4 (Accession 0001104659-26-077426).